Literature DB >> 23907832

Persistent sterile peritoneal inflammation after catheter removal for refractory bacterial peritonitis predicts full-blown encapsulating peritoneal sclerosis.

Yuk-Yi Wong1, Ping-Nam Wong, Siu-Ka Mak, Shuk-Fan Chan, Yuen-Yi Cheuk, Lo-Yi Ho, Kin-Yee Lo, Man-Wai Lo, Kwok-Chi Lo, Gensy Mei-Wah Tong, Andrew Kui-Man Wong.   

Abstract

BACKGROUND: Encapsulating peritoneal sclerosis (EPS) is the most serious complication of peritoneal dialysis, having high morbidity and mortality. To improve outcomes, early diagnosis is needed to direct treatment during the early inflammatory phase. However, in the early inflammatory phase, clinical features are nonspecific, and no reliable diagnostic criteria have been established. Because bacterial peritonitis and termination of dialysis are two important risk factors triggering the progression of EPS, patients with refractory bacterial peritonitis necessitating dialysis catheter removal are at particularly high risk of developing EPS. Many of these patients might indeed experience non-resolving sterile peritonitis (probably the inflammatory phase of EPS) before progression to full-blown disease (that is, the presence of intestinal obstruction). We undertook a retrospective study to compare, in this particular situation, the clinical characteristics of patients with or without sterile peritoneal inflammation, assessing their clinical outcomes in terms of short-term mortality and the chance of developing full-blown EPS.
METHODS: Our retrospective review included 62 patients whose dialysis catheter was removed because of refractory peritonitis between January 2005 and December 2010.
RESULTS: Of the 62 patients identified, 39 (63%) had persistent sterile peritoneal inflammation ("high-risk" group, n = 39), and 23 (37%) had resolution of inflammation without significant intra-abdominal collection after catheter withdrawal ("control" group, n = 23). Compared with the control group, the high-risk group had a significantly longer PD duration (71.6 ± 43.3 months vs 42.3 ± 29.9 months, p = 0.003), a higher dialysate-to-plasma ratio (D/P) of creatinine (0.768 ± 0.141 vs 0.616 ± 0.091, p = 0.004), and a higher computed tomography score for EPS (7.69 ± 2.98 vs 1.00 ± 1.00, p < 0.001). During the 6-month study period, the high-risk group had a higher chance of developing full-blown EPS (31% vs 0%, p = 0.002) and a higher 6-month all-cause mortality (36% vs 4.3%, p = 0.004).
CONCLUSIONS: Persistent sterile peritoneal inflammation was common after dialysis catheter removal for refractory bacterial peritonitis, and the patients with such inflammation were at high risk of progression to full-blown EPS.

Entities:  

Keywords:  Catheter removal; encapsulating peritoneal sclerosis; mortality; refractory peritonitis

Mesh:

Year:  2013        PMID: 23907832      PMCID: PMC3797669          DOI: 10.3747/pdi.2012.00281

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  20 in total

1.  Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study.

Authors:  Hideki Kawanishi; Yoshindo Kawaguchi; Hiroyoshi Fukui; Shigeko Hara; Akio Imada; Hitoshi Kubo; Masao Kin; Masahiko Nakamoto; Seiji Ohira; Takao Shoji
Journal:  Am J Kidney Dis       Date:  2004-10       Impact factor: 8.860

2.  Persistent symptomatic intra-abdominal collection after catheter removal for PD-related peritonitis.

Authors:  Cheuk-Chun Szeto; Bonnie Ching-Ha Kwan; Kai-Ming Chow; Wing-Fai Pang; Vickie Wai-Ki Kwong; Chi-Bon Leung; Philip Kam-Tao Li
Journal:  Perit Dial Int       Date:  2010-05-06       Impact factor: 1.756

3.  The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis.

Authors:  Gowrie Balasubramaniam; Edwina A Brown; Andrew Davenport; Hugh Cairns; Barbara Cooper; Stanley L S Fan; Ken Farrington; Hugh Gallagher; Patrick Harnett; Sally Krausze; Simon Steddon
Journal:  Nephrol Dial Transplant       Date:  2009-02-11       Impact factor: 5.992

4.  Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD.

Authors:  Edwina A Brown; Wim Van Biesen; Fredric O Finkelstein; Helen Hurst; David W Johnson; Hideki Kawanishi; Roberto Pecoits-Filho; Graham Woodrow
Journal:  Perit Dial Int       Date:  2009 Nov-Dec       Impact factor: 1.756

5.  Risk factors associated with encapsulating peritoneal sclerosis in Dutch EPS study.

Authors:  Mario R Korte; Denise E Sampimon; Hester F Lingsma; Marien W Fieren; Caspar W N Looman; Robert Zietse; Willem Weimar; Michiel G H Betjes
Journal:  Perit Dial Int       Date:  2011-03-31       Impact factor: 1.756

6.  Sclerosing peritonitis: the experience in Australia.

Authors:  R J Rigby; C M Hawley
Journal:  Nephrol Dial Transplant       Date:  1998-01       Impact factor: 5.992

7.  Sclerosing obstructive peritonitis after continuous ambulatory peritoneal dialysis.

Authors:  J A Bradley; D L McWhinnie; D N Hamilton; F Starnes; S G Macpherson; M Seywright; J D Briggs; B J Junor
Journal:  Lancet       Date:  1983-07-09       Impact factor: 79.321

8.  Screening for encapsulating peritoneal sclerosis in patients on peritoneal dialysis: role of CT scanning.

Authors:  Catriona Goodlad; Ruth Tarzi; Wladyslaw Gedroyc; Adrian Lim; Steven Moser; Edwina A Brown
Journal:  Nephrol Dial Transplant       Date:  2010-09-01       Impact factor: 5.992

9.  Early diagnostic markers for encapsulating peritoneal sclerosis: a case-control study.

Authors:  Denise E Sampimon; Mario R Korte; Deirisa Lopes Barreto; Anniek Vlijm; Rudy de Waart; Dirk G Struijk; Raymond T Krediet
Journal:  Perit Dial Int       Date:  2010-02-01       Impact factor: 1.756

10.  Encapsulating peritoneal sclerosis in the new millennium: a national cohort study.

Authors:  Michaela C Brown; Keith Simpson; Jan J Kerssens; Robert A Mactier
Journal:  Clin J Am Soc Nephrol       Date:  2009-06-18       Impact factor: 8.237

View more
  11 in total

1.  Towards standardized reporting in studies of encapsulating peritoneal sclerosis.

Authors:  Mark Lambie; Niko Braun; Simon J Davies
Journal:  Perit Dial Int       Date:  2013 Sep-Oct       Impact factor: 1.756

2.  Peritoneal Dialysis-Associated Peritonitis Caused by Mycobacterium abscessus.

Authors:  Tsung-Kun Yang; Jia-Jung Lee; Po-Liang Lu; Hung-Tien Kuo; Mei-Chuan Kuo; Hung-Chun Chen
Journal:  Perit Dial Int       Date:  2015 May-Jun       Impact factor: 1.756

3.  Trial of short-course antimicrobial therapy for intraabdominal infection.

Authors:  Robert G Sawyer; Jeffrey A Claridge; Avery B Nathens; Ori D Rotstein; Therese M Duane; Heather L Evans; Charles H Cook; Patrick J O'Neill; John E Mazuski; Reza Askari; Mark A Wilson; Lena M Napolitano; Nicholas Namias; Preston R Miller; E Patchen Dellinger; Christopher M Watson; Raul Coimbra; Daniel L Dent; Stephen F Lowry; Christine S Cocanour; Michaela A West; Kaysie L Banton; William G Cheadle; Pamela A Lipsett; Christopher A Guidry; Kimberley Popovsky
Journal:  N Engl J Med       Date:  2015-05-21       Impact factor: 91.245

4.  Risk factors for drainage-requiring ascites after refractory peritonitis in peritoneal dialysis patients.

Authors:  Cheng-Chia Lee; Kun-Hua Tu; Hsiao-Hui Chen; Ming-Yang Chang; Cheng-Chieh Hung
Journal:  Int Urol Nephrol       Date:  2016-08-05       Impact factor: 2.370

5.  Short-Course Antimicrobial Therapy for Intraabdominal Infection.

Authors:  Christopher A Guidry; Robert G Sawyer
Journal:  N Engl J Med       Date:  2015-10-15       Impact factor: 91.245

Review 6.  Designing Epidemiology Studies to Determine the Incidence and Prevalence of Encapsulating Peritoneal Sclerosis (EPS).

Authors:  Dorothea Nitsch; Andrew Davenport
Journal:  Perit Dial Int       Date:  2015-12       Impact factor: 1.756

7.  Encapsulating Peritoneal Sclerosis - A rare and serious complication of peritoneal dialysis: Case series.

Authors:  O Mihalache; C Bugă; H Doran; E Catrina; F Bobircă; T Pătrașcu
Journal:  J Med Life       Date:  2014

8.  Analysis of early mesothelial cell responses to Staphylococcus epidermidis isolated from patients with peritoneal dialysis-associated peritonitis.

Authors:  Amanda L McGuire; Kieran T Mulroney; Christine F Carson; Ramesh Ram; Grant Morahan; Aron Chakera
Journal:  PLoS One       Date:  2017-05-24       Impact factor: 3.240

9.  Anti-fibrotic effect of decorin in peritoneal dialysis and PD-associated peritonitis.

Authors:  Na Jiang; Qing Zhang; Mel Km Chau; Ming S Yip; Sing Leung Lui; Stephanie Liu; Kent Man Chu; Hextan Ys Ngan; Tak Mao Chan; Susan Yung
Journal:  EBioMedicine       Date:  2020-02-12       Impact factor: 8.143

10.  Clinical risk factors and outcomes of massive ascites accumulation after discontinuation of peritoneal dialysis.

Authors:  Ming-Shan Chang; Nai-Ching Chen; Chih-Yang Hsu; Chien-Wei Huang; Po-Tsang Lee; Kang-Ju Chou; Hua-Chang Fang; Chien-Liang Chen
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.